Poster presentation highlighted promising pharmacology and behavioral results on lead candidate, TN-001, in preclinical studies. TN-001 is under development for both major depressive disorder (MDD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback